PDCD1 and hematologic disorder: Blockade of PD-1 or PD-L1 improves T-cell-mediated killing of tumor cells, and antibodies targeting PD-1 and PD-L1 have shown marked clinical activity in solid tumors [18,19], as well as in hematologic malignancies such as Hodgkin lymphoma [20].